Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Division of Pulmonary Medicine.
Ann Am Thorac Soc. 2023 Nov;20(11):1605-1613. doi: 10.1513/AnnalsATS.202302-117OC.
Little is known about the long-term impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on children with asthma. To determine whether SARS-CoV-2 infection affects symptom control and lung function in children with asthma. Using data from clinical registries and the electronic health record, we conducted a prospective case-control study of children with asthma aged 6-21 years who had (cases) or did not have (control subjects) SARS-CoV-2 infection, comparing baseline and follow-up asthma symptom control and spirometry within an ∼18-month time frame and, for cases, within 18 months of acute coronavirus disease (COVID-19). A total of 171 cases had baseline and follow-up asthma symptom data, and 114 cases had baseline and follow-up spirometry measurements. There were no significant differences in asthma symptom control ( = 0.50), forced expiratory volume in 1 second ( = 0.47), forced vital capacity ( = 0.43), forced expiratory volume in 1 second/forced vital capacity ( = 0.43), or forced expiratory flow, midexpiratory phase ( = 0.62), after SARS-CoV-2 infection. Compared with control subjects (113 with symptom data and 237 with spirometry data), there were no significant differences in follow-up asthma symptom control or lung function. A similar proportion of cases and control subjects had poorer asthma symptom control (17.5% vs. 9.7%; = 0.07) or worse lung function (29.0% vs. 32.5%; = 0.50) at follow-up. Patients whose asthma control worsened after COVID-19 had a shorter time to follow-up (3.5 [1.5-7.5] vs. 6.1 [3.1-9.8] mo; = 0.007) and were more likely to have presented with an asthma exacerbation during COVID-19 (46% vs. 26%; = 0.04) than those without worse control. We found no significant differences in asthma symptom control or lung function in youth with asthma up to 18 months after acute COVID-19, suggesting that COVID-19 does not affect long-term asthma severity or control in the pediatric population.
目前对于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染对哮喘儿童的长期影响知之甚少。为了确定 SARS-CoV-2 感染是否会影响哮喘儿童的症状控制和肺功能,我们使用临床登记处和电子健康记录中的数据,对 6-21 岁患有 SARS-CoV-2 感染(病例)或未感染 SARS-CoV-2 感染(对照)的哮喘儿童进行了前瞻性病例对照研究,比较了约 18 个月的时间内哮喘症状控制和肺活量,并对病例进行了急性冠状病毒病(COVID-19)后 18 个月的比较。共有 171 例病例有基线和随访哮喘症状数据,114 例病例有基线和随访肺活量测量值。在 SARS-CoV-2 感染后,哮喘症状控制( = 0.50)、1 秒用力呼气量( = 0.47)、用力肺活量( = 0.43)、1 秒用力呼气量/用力肺活量( = 0.43)或用力呼气中期流量( = 0.62)均无显著差异。与对照组(113 例有症状数据和 237 例有肺活量数据)相比,随访时哮喘症状控制或肺功能无显著差异。病例和对照组中,有相似比例的患者在随访时哮喘症状控制较差(17.5%比 9.7%; = 0.07)或肺功能更差(29.0%比 32.5%; = 0.50)。COVID-19 后哮喘控制恶化的患者随访时间更短(3.5[1.5-7.5]比 6.1[3.1-9.8]月; = 0.007),且更有可能在 COVID-19 期间发生哮喘加重(46%比 26%; = 0.04),而非控制恶化的患者。我们发现,在急性 COVID-19 后长达 18 个月,哮喘儿童的哮喘症状控制或肺功能无显著差异,表明 COVID-19 不会影响儿科人群的长期哮喘严重程度或控制。